JBIO Aerovate Therapeutics, Inc. Insider Trading

CEO Frohlich buys 6,000 shares of JBIO at $7.40; first holding post-IPO at recently-listed company with $-2.5M net income

Tom Frohlich, Chief Executive Officer of Jade Biosciences, purchased 6,000 shares at $7.40 on 2025-05-16, establishing his first position in the company just 15 trading days after the recent listing. The purchase occurred at a company with a $-2.5M net income in its most recent fiscal year, indicating material unprofitability. The transaction value of $44,400.00 and the CEO's initial entry into ownership during the early post-IPO phase warrant investor attention to both the leadership's personal capital commitment and the company's near-term operational trajectory.

RA Capital Management purchased 928,110 shares at $1.67; stock now down 95.2% from 52-week high despite 13.3% increase in director's holdings.

RA Capital Management, as a Director and substantial shareholder, purchased 928,110 shares at $1.67 on 2024-06-17, increasing holdings to 7,893,678 shares. The company is unprofitable with full-year net income of $-23,186,000.00 and currently trades at $51.10, down 95.2% from its 52-week high of $1076.25. The director's cross-ticker track record shows mixed results (19 prior buys averaging -6.4% 30-day returns and +13.3% 90-day returns with a 61.54% win rate), suggesting this purchase does not represent a universally predictive signal. The severe price deterioration from the transaction date and the company's unprofitable status place this transaction in a context of significant fundamental and valuation stress.